TOLEDO, Ohio & REDWOOD CITY, Calif.--(BUSINESS WIRE)--Avinger Inc., pioneer of the lumivascular approach for treating vascular disease announced today that Dr. John Pigott of Jobst Vascular Institute, Toledo, OH, enrolled the first patient in VISION. VISION is a global IDE clinical trial, approved by the FDA to evaluate Avinger’s PantherisTM catheter for the treatment of Peripheral Artery Disease (PAD). It is estimated that PAD affects 12 million people in the US alone.
Help employers find you! Check out all the jobs and post your resume.
